Stem Cells International / 2024 / Article / Tab 1 / Review Article
Different Levels of Autophagy Activity in Mesenchymal Stem Cells Are Involved in the Progression of Idiopathic Pulmonary Fibrosis Table 1 Role of autophagy in the therapeutic potential of MSCs.
Disease model Mechanism Autophagy effect Reference Ischemic stroke MSCs inhibit autophagy and promote cell survival by transferring miR-25 to support recovery of neurological function after stroke Negative [57 ] Liver fibrosis Autophagy inhibition via Becn1 downregulation improves the MSCs antifibrotic potential Negative [58 ] Hypoxic-ischemic brain damage MSCs reduce autophagy in hippocampal neurons partly through the AMPK/mTOR pathway Negative [59 ] Osteoarthritis MSCs enhance autophagy in chondrocytes via mTOR inhibition and protect articular cartilage from damage Positive [60 ] Acute lung injury MSCs enhance autophagy and ameliorate acute lung injury partially via delivery of miR-100 Positive [61 ] Idiopathic pulmonary fibrosis Inhibition of miR-199a-5p enhances autophagy by regulating the Sirt1/AMPK signaling pathway and rejuvenates IPF-MSCs senescence Positive [62 ] Parkinson’s disease MSCs enhance autophagy and exert a neuroprotective effect through the modulation of α -synuclein Positive [63 ] Alzheimer’s disease MSCs enhance autophagy and increase β -amyloid clearance to improve neuronal survival against Aβ toxicity Positive [64 ] Inflammatory bowel disease Enhancement of autophagy in MSCs improves immunosuppression of MSCs by increasing Pacer levels Positive [65 ] Diabetic kidney disease MSCs diminish cell death in kidney tissue facing diabetic kidney disease, culminating in podocyte maintenance, and also downregulating the over induction of the autophagy pathway A double-edged sword [66 ]